| Literature DB >> 30410779 |
Michael S Salman1, Shakhawat Hossain2, Lina Alqublan3,4, Martin Bunge5, Katya Rozovsky5.
Abstract
BACKGROUND: Many children with neurofibromatosis type 1 (NF1) have focal abnormal signal intensities (FASI) on brain MRI, whose full clinical impact and natural history have not been studied systematically. Our aims are to describe the clinical and neuroradiological features in children with NF1 and cerebellar FASI, and report on the natural history of FASI that display atypical features such as enhancement and mass effect.Entities:
Keywords: Cerebellum; Clinical features; Neurofibromatosis type 1; Neuroimaging; Pediatrics
Year: 2018 PMID: 30410779 PMCID: PMC6211433 DOI: 10.1186/s40673-018-0093-y
Source DB: PubMed Journal: Cerebellum Ataxias ISSN: 2053-8871
Demographics of NF1 patients
| Details | |
|---|---|
| Total number of patients | 50 |
| Gender M/F | 27/23 |
| Mean age [SD] at end of study in years (y) | 16.13 [5.5] |
| Median age [min.-max.] at symptom/ sign onset (y) | 0.4 [0.00–8.5] |
| Median age [min.-max.] at first clinical assessment (y) | 1.9 [0.3–16.3] |
| Median age [min.-max.] at diagnosis of NF1 (y) | 2.2 [0.00–11.3] |
| Mean age [SD] at last clinical assessment (y) | 13.6 [6.4] |
| Mean duration [SD] of clinical follow up (y) | 10.1 [5.9] |
| Total number of deaths | 4 |
| Median age [min.-max.] at death (y) | 18.2 [2.3–28.1] |
| Median maternal age {25th–75th %} and [min.-max.] at birth (y) | 27 {21–32}, [17–52] |
min. minimum, max. maximum
Mortality in NF1 patients
| Age at death (y) | Sex | Diagnosis |
|---|---|---|
| 2.3 | M | High grade pilomyxoid astrocytoma of the hypothalamus presenting with symptoms and signs of raised intracranial pressure |
| 13.0 | M | Disseminated metastatic high grade undifferentiated sarcoma with neuronal phenotype presenting with spinal cord compression |
| 23.4 | F | High grade malignant peripheral nerve sheath tumor presenting with cauda equina syndrome |
| 28.1 | M | Metastatic high grade spindle cell sarcoma arising from the pelvis and presenting with hematuria and bilateral hydronephrosis |
Maternal health, pregnancy and labor for NF1 patients
| Number of patients (%) | a Total number of patients | |
|---|---|---|
| Maternal health prior to pregnancy | ||
| NF1 | 7 (20.6) | 34 |
| History of spontaneous fetal loss | 9 (18) | 50 |
| Gestational hypertension | 7 (18.4) | 38 |
| Fetal exposures during pregnancy | ||
| Smoking | 9 (33.3) | 27 |
| Alcohol | 6 (22.2) | 27 |
| Marijuana | 4 (16.7) | 24 |
| Radiation | 1 (12.5) | 8 |
| Delivery | 42 | |
| Uncomplicated SVD | 32 (76.2) | |
| b Complicated SVD | 3 (7.1) | |
| Planned C/S | 5 (11.9) | |
| Emergency C/S | 2 (4.8) | |
| Gestational age in weeks | 42 | |
| Term (≥ 37 weeks) | 36 (85.7) | |
| 36 weeks | 5 (11.9) | |
| 33 weeks | 1 (2.4) | |
a Number of patients where the information is available, b complicated spontaneous vaginal delivery (SVD) e.g. nuchal cord, breech, shoulder dystocia, forceps or vacuum extraction, C/S: Caesarian section
Reason(s) for the initial clinical assessment of NF1 patients (N = 50)
| Clinical features | Number of patients (%) |
|---|---|
| Café-au-lait macules | 42 (84) |
| Positive family history of NF1 | 13 (26) |
| Developmental delay | 5 (10) |
| Neurofibroma(s) | 3 (6) |
| Failure to thrive | 3 (6) |
| Bony abnormality | 2 (4) |
| Hypotonia | 2 (4) |
| Seizures | 2 (4) |
| Change in vision | 2 (4) |
| Incidental findings on imaging | 2 (4) |
| Tumor | 1 (2) |
| Learning disabilities | 1 (2) |
| Behavioural concerns | 1 (2) |
Clinical features in patients with NF1
| Number of patients (%) | a Total number of patients | |
|---|---|---|
| Learning disability | 25 (65.8) | 38 |
| Developmental delay | 20 (43.5) | 46 |
| Speech/language | 10 (21.7) | |
| Global | 9 (19.6) | |
| Gross motor | 1 (2.2) | |
| Headache | 17 (34) | b 50 |
| ADHD | 14 (28) | b 50 |
| Seizures | 8 (16.3) | 49 |
| Hypertension | 2 (4.8) | 42 |
| Neurofibromas | 27 (71.1) | 38 |
| Excision and/ or debulking of neurofibromas | 7 of 27 | |
| Other tumors | 28 (59.6) | 47 |
| Tumor resection | 8 of 28 | |
| Type of other tumors | ||
| Optic pathways glioma | 21 (44.7) | |
| Sarcoma | 4 (8.5) | |
| Astrocytoma | 4 (8.5) | |
| Hemangioma | 2 (4.3) | |
| Glioma (excluding optic pathways) | 1 (2.1) | |
| Craniopharyngioma | 1 (2.1) | |
| Wilm’s tumor | 1 (2.1) | |
| Ovarian renin-secreting tumor | 1 (2.1) | |
| Bony abnormalities | 17 (51.5) | 33 |
| Scoliosis | 12 (36.4) | |
| Other | 4 (12.1) | |
| Sphenoid bone dysplasia | 1 (3.3) | |
| Family history of NF1 | 50 | |
| Absent | 26 (52) | |
| First-degree relative | 10 (20) | |
| First and second-degree relative | 11 (22) | |
| First, second and third-degree relative | 3 (6) | |
| Café-au-lait macules | 50 (100) | 50 |
| Axillary and/ or inguinal freckling | 40 (88.89) | 45 |
| Axillary only | 18 (40) | |
| Inguinal only | 2 (4.4) | |
| Both axillary and inguinal | 20 (44.4) | |
| Decreased visual acuity | 9 (19.1) | 47 |
| Abnormal visual fields | 12 (38.7) | 31 |
| Lisch nodules | 17 (47.2) | 36 |
| Optic disc pallor | 18 (40.9) | 44 |
| Abnormal pupillary response | 5 (12.2) | 41 |
| Strabismus | 10 (34.5) | 29 |
| Nystagmus | 4 (25) | 16 |
| Decreased tone | 9 (23.1) | 39 |
| Increased tone | 3 (7.7) | 39 |
| Decreased strength | 6 (15.4) | 39 |
| Increased upper/ lower limb reflexes | 3 (7.9)/ 8 (21.1) | 38 |
| Decreased upper/ lower limb reflexes | 4 (10.5)/ 2 (5.3) | 38 |
| Clonus | 2 (16.7) | 12 |
| Babinski sign | 3 (8.6) | 35 |
| Wheelchair use or other assistive devices | 3 (6.8) | 44 |
| Clumsy gait and/ or difficulty with fine motor coordination | 20 (40) | 50 |
a Number of patients where the information is available, b the number of patients without headache and attention deficit hyperactivity disorder (ADHD) was not reported; therefore, the percentage represents the least proportion of patients with headaches and ADHD in our cohort
The number (no.) of patients with focal abnormal signal intensities (FASI) and the total number of FASI in different brain locations at baseline MRI in all patients
| No. of patients | Mean age at MRI (95% CI) in years | The no. of patients with FASI per brain region: | |||||
| Cerebellum | Brainstem | Thalamus | Hypothalamus | Basal ganglia | Cerebrum | ||
| 50 | 7.8 (6.5–9.1) | 49 | 31 | 14 | 3 | 36 | 17 |
| a Median no. of FASI (min.-max.) per patient | Total no. of FASI in all patients | The total no. (%) of FASI in all patients per brain region: | |||||
| Cerebellum | Brainstem | Thalamus & hypothalamus | Basal ganglia | Cerebrum | |||
| 7 (2–17) | 339 | 136 (40.1) | 82 (24.2) | 28 (8.3) | 65 (19.2) | a28 (8.3) | |
a One patient with the numerous cerebral lesions is excluded, min. minimum, max. maximum
The distribution pattern of focal abnormal signal intensities (FASI) on baseline MRI in all 50 patients
| Brain location | Number of patient(s) |
|---|---|
| Cerebellum, brainstem, and (thalamus or basal ganglia) | 17 |
| Cerebellum, brainstem, cerebrum, and (thalamus or basal ganglia) | 9 |
| Cerebellum and basal ganglia | 4 |
| Cerebellum only | 3 |
| Cerebellum and cerebrum | 3 |
| Cerebellum, cerebrum, and (thalamus or basal ganglia) | 3 |
| Cerebellum and brainstem | 2 |
| Cerebellum, thalamus, and basal ganglia | 2 |
| Cerebellum, brainstem, and cerebrum | 2 |
| Cerebellum and thalamus | 1 |
| Cerebellum and hypothalamus | 1 |
| Cerebellum, basal ganglia, and hypothalamus | 1 |
| Cerebellum, brainstem, basal ganglia, and hypothalamus | 1 |
| Basal ganglia only initially then middle cerebellar peduncle involvement subsequently | 1 |
Details of patients with NF1 showing mass effect and/or enhancement of focal abnormal signal intensities (FASI)
| Patient study number | Age at finding in years (y) | Location | FASI diameter(cm) | Mass effect | Enhancement | FASI outcome |
|---|---|---|---|---|---|---|
| 7 | 17.7 | L cerebellum, R basal ganglia | 1.2, 0.8 | – | + | Remained stable in size with persisting enhancement on a repeat scan 1.3y later. Died at age 28.1y from a pelvic sarcoma |
| 8 | 12.8 | L cerebellum | 3.7 | + initially only | + | Enlarged to 4 cm at age 13.1y then shrunk to 2.8 cm with resolution of mass effect and enhancement at age 13.5y. Disappeared at 21.3y |
| 12.8 | R cerebellum | 2 | + | + | Enlarged to 2.7 cm. Partial excision at age 13y (benign ganglioma). Remnant enhanced then resolved at age 21.8y. Died at age 23.4y from a malignant nerve sheath tumor | |
| 13 | 2.8 | L cerebellum | 1.2 | + | – | Decreased to 0.8 cm with resolution of mass effect at age 5.5y. Disappeared at age 7.6y |
| 2.8 | R cerebellum | 1 | – | + | Decreased to 0.5 cm with resolution of enhancement at age 5.5y. Disappeared at age 7.6y | |
| 7 | R cerebellum | 0.8 | + | + | Resolved at age 11.2y | |
| 20 | 1.9 | L thalamus | 1.6 | + | – | Resolved at age 2.3y |
| 33 | 3 | R periventricular region | 5.6 (few confluent FASI) | + initially only | + at 4.6y | Diameter was 4 cm and enhancement persisted on last scan at age 16y |
| 3 | Midbrain | 1.6 | – | + | Resolved at age 4y | |
| 41 | 11.7 | Pons/ L superior cerebellar peduncle | 1.6 | + | + | Enlarged to 2.2 cm at age 17.2y then shrunk to 1.3 cm with resolution of mass effect at age 19.9y. Enhancement persisted on last scan at age 19.9y |
| 14.2 | L cerebellum | 0.8 | – | + at 18.8y | Enlarged to 2 cm and developed into a cystic lesion with a solid component. Fully resected and proven to be a low grade pilocytic astrocytoma | |
| 44 | 1.8 | Bilateral basal ganglia | 4.9 each | + | + | Shrunk to 2.5, 2.7 cm at age 2.3y then enlarged to 3.9, 5 cm on last scan at age 3.8y. Both mass effect and enhancement persisted |
| 1.8 | L fornix | 1.4 | + initially only | – | Enlarged to 2.5 cm at age 2.3y and to 2.7 cm on last scan at age 3.8y | |
| 1.8 | Bilateral cerebral peduncles | 1.7, 1.4 | + initially only | + | Size remained stable and enhancement persisted on last scan at age 3.8y | |
| 50 | 18.1 | R periventricular region | 2 | + at 29.3y | + at 27.4y | Enlarged to 6.7 cm then showed necrosis at age 28.3y, followed by further enlargement to 10.5 cm with edema and mass effect at age 29.3y. Resected and proven to be an anaplastic astrocytoma |
| 28 | Corpus callosum | 1.7 | – | + | Enlarged to 2.4 cm at age 28.5y then shrunk to 1.9 cm on last scan at age 29.3y with a persisting enhancement | |
| 54 | 3.7 | L subcortical white matter | 0.5 | – | + at 5.3y | Enlarged to 1.4 cm at age 5.3y then shrunk to 1 cm at age 5.8y. Remained the same size with persistent enhancement on last scan at age 9.2y |
L left, R right, − absent, + present
Fig. 1A coronal T1-weighted brain MRI of a 22 months old female with NF1 is shown. There is heterogeneous contrast enhancement involving the basal ganglia and internal capsule bilaterally
Fig. 2An axial brain MRI of a 22 months old female with NF1 is shown. There are bilateral extensive confluent areas of FLAIR signal abnormalities with increased signal intensity involving the internal capsule bilaterally, basal ganglia, thalami, hypothalamus, and cerebral peduncles. There is mass effect on the posterior horns of the lateral ventricles and on the third ventricle causing dilatation of the posterior horns
Fig. 3An axial T1-weighted MRI in a two-year old male with NF1 without contrast (A) and with contrast (B) showing an enhancing lesion within the hypothalamus (arrow)